Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Stock Information for Mersana Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mersana Therapeutics Inc.

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
Mersana Therapeutics to Present at Upcoming Investor Conferences
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.